文献速递肿瘤 PET/CT

[68Ga]Ga-NY104 PET/CT 识别透明细胞肾细胞癌的诊断效能

Diagnostic efficacy of [68Ga]Ga-NY104 PET/CT to identify clear cell renal cell carcinoma.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-06-25

研究前瞻性纳入47例患者,分原发肾肿块拟手术组(20例)和疑似/确诊转移性透明细胞肾细胞癌组(27例),均行[68Ga]Ga-NY104 PET/CT。患者水平敏感度、特异度、准确度在原发组为62%、33%、58%,在转移组为95%、100%、96%;[68Ga]Ga-NY104 PET在67%(14/21)患者中识别出26个既往未知病灶区域,肿瘤摄取与免疫组化染色结果相关。结论认为该显像对转移性透明细胞肾细胞癌诊断效能高,对原发透明细胞肾细胞癌诊断价值可能有限。

要点

  • 转移性ccRCC组患者水平敏感度95%、特异度100%、准确度96%。
  • 原发ccRCC组患者水平敏感度62%、特异度33%、准确度58%。
  • [68Ga]Ga-NY104 PET在67%(14/21)患者中识别出26个既往未知病灶区域。

核心结论

  • [68Ga]Ga-NY104 PET/CT对转移性透明细胞肾细胞癌患者具有高诊断效能,而对原发透明细胞肾细胞癌的诊断价值可能有限。

研究设计与样本

  • 前瞻性研究(ClinicalTrials.gov: NCT05902377),共纳入47例患者(平均年龄58.8岁±13.5,34名男性),分为原发肾肿块拟手术组20例和疑似/确诊转移性透明细胞肾细胞癌组27例,所有患者均行[68Ga]Ga-NY104 PET/CT。

主要发现

  • 患者水平敏感度、特异度、准确度在原发组分别为62%、33%、58%,在转移组分别为95%、100%、96%。
  • [68Ga]Ga-NY104 PET在67%(14/21)患者中识别出26个既往未知病灶区域。
  • 肿瘤摄取与免疫组化染色结果相关。

关键数值与推荐

  • 原发肾肿块拟手术组患者水平敏感度62%、特异度33%、准确度58%。
  • 疑似/确诊转移性透明细胞肾细胞癌组患者水平敏感度95%、特异度100%、准确度96%。

临床怎么用

  • 原文结论未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Most clear cell renal cell carcinoma (ccRCC) overexpresses carbonic anhydrase IX (CAIX). [68Ga]Ga-NY104 is a small-molecule PET agent selectively targeting CAIX. This study aims to assess the efficacy of [68Ga]Ga-NY104 PET/CT to identify ccRCC. MATERIALS AND METHODS: Participants were prospectively recruited in the study (ClinicalTrials.gov: NCT05902377). They were further divided into two groups: group 1, patients with primary renal mass who were scheduled for surgery, group 2, patients with suspected/confirmed metastatic ccRCC. All patients underwent [68Ga]Ga-NY104 PET/CT. RESULTS: A total of 47 patients (mean age, 58.8 years ± 13.5, 34 men) were recruited, including 20 patients in group 1 and 27 patients in group 2. The patient-level sensitivity, specificity, and accuracy of [68Ga]Ga-NY104 PET scan was 62%, 33%, 58% for group 1 and 95%, 100%, 96% for group 2. [68Ga]Ga-NY104 PET identified additional 26 disease regions in 67% (14/21) of patients that were previously unknown. The tumor uptake was correlated with immunohistochemical staining results. CONCLUSIONS: [68Ga]Ga-NY104 PET/CT has a high diagnostic efficacy for patients with metastatic ccRCC, while it might be of limited value in the diagnosis of primary ccRCC.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Zhu W, Zheng G, Yan X, et al. Diagnostic efficacy of [68Ga]Ga-NY104 PET/CT to identify clear cell renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2024. PMID: 38916753. doi:10.1007/s00259-024-06801-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。